| scholarly article | Q13442814 |
| P50 | author | José Félix Martí Massó | Q59546069 |
| Adolfo López de Munain | Q64780336 | ||
| P2093 | author name string | A Gorostidi | |
| J Ruiz-Martínez | |||
| A Alzualde | |||
| P2860 | cites work | Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 |
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Diagnostic criteria for Parkinson disease | Q34489839 | ||
| G2019S LRRK2 mutation in French and North African families with Parkinson's disease | Q39171895 | ||
| High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal | Q45281911 | ||
| Is the G2019S LRRK2 mutation common in all southern European populations? | Q46948308 | ||
| LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance | Q46988538 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. | Q54683068 | ||
| Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain | Q57983267 | ||
| LRRK2 mutations are a common cause of Parkinson's disease in Spain | Q57983278 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease | Q58870346 | ||
| Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques | Q80314487 | ||
| P433 | issue | 2 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 157-159 | |
| P577 | publication date | 2008-11-20 | |
| P1433 | published in | Neurogenetics | Q15710048 |
| P1476 | title | LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity | |
| P478 | volume | 10 |
| Q61805965 | A Comprehensive Analysis of Population Differences in Variant Distribution in Parkinson's Disease |
| Q92202029 | Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls |
| Q38433725 | Cellular processes associated with LRRK2 function and dysfunction |
| Q22252904 | Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update |
| Q38164890 | Genetic testing of LRRK2 in Parkinson's disease: is there a clinical role? |
| Q26827825 | Genetics of Parkinson's disease |
| Q44199951 | High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain) |
| Q36477677 | Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity |
| Q55410950 | LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. |
| Q42927984 | LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity |
| Q47718405 | LRRK2 gene variation and its contribution to Parkinson disease |
| Q53209404 | LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation |
| Q92933189 | LRRK2 in Parkinson disease: challenges of clinical trials |
| Q37608624 | LRRK2 in Parkinson's disease: genetic and clinical studies from patients |
| Q37635000 | LRRK2: Cause, Risk, and Mechanism |
| Q38738200 | Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q39465478 | Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease |
| Q54978235 | Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. |
| Q38273952 | Neurogenetic disorders in the Basque population |
| Q46521682 | Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations |
| Q44350484 | Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. |
| Q34121655 | Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 |
| Q37597933 | The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews |
| Q55265334 | The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. |
| Q40783163 | The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot |
| Q34513714 | The genetic background of Parkinson's disease: current progress and future prospects |
| Q33767528 | Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. |
| Q34540556 | Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers |
Search more.